243 related articles for article (PubMed ID: 24413830)
1. Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?
Cananzi FC; Lorenzi B; Belgaumkar A; Benson C; Judson I; Mudan S
Langenbecks Arch Surg; 2014 Mar; 399(3):323-32. PubMed ID: 24413830
[TBL] [Abstract][Full Text] [Related]
2. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
[TBL] [Abstract][Full Text] [Related]
3. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
[TBL] [Abstract][Full Text] [Related]
5. Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors.
Zaydfudim V; Okuno SH; Que FG; Nagorney DM; Donohue JH
J Surg Res; 2012 Oct; 177(2):248-54. PubMed ID: 22831567
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal stromal tumors (GIST): a single center experience.
Kostka R; Gürlich R; Koldová L
Acta Chir Belg; 2012 Jan; 112(1):33-9. PubMed ID: 22442907
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).
Bauer S; Rutkowski P; Hohenberger P; Miceli R; Fumagalli E; Siedlecki JA; Nguyen BP; Kerst M; Fiore M; Nyckowski P; Hoiczyk M; Cats A; Casali PG; Treckmann J; van Coevorden F; Gronchi A
Eur J Surg Oncol; 2014 Apr; 40(4):412-9. PubMed ID: 24491288
[TBL] [Abstract][Full Text] [Related]
8. Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.
Cananzi FC; Belgaumkar AP; Lorenzi B; Mudan S
ANZ J Surg; 2014 Dec; 84(12):E1-8. PubMed ID: 23647808
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib.
Chang SC; Liao CH; Wang SY; Tsai CY; Chiang KC; Cheng CT; Yeh TS; Chen YY; Ma MC; Liu CT; Yeh CN
Medicine (Baltimore); 2015 Jun; 94(24):e1014. PubMed ID: 26091448
[TBL] [Abstract][Full Text] [Related]
10. Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.
Cananzi FC; Belgaumkar A; Lorenzi B; Mudan S
ANZ J Surg; 2014 Dec; 84(12):937-42. PubMed ID: 25444423
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in surgically managed gastrointestinal stromal tumours.
Wu XJ; Zhang RX; Chen G; Fang YJ; Ding PR; Li LR; Lu ZH; Kong LH; Pan ZZ; Wan DS
J Int Med Res; 2012; 40(5):1904-11. PubMed ID: 23206474
[TBL] [Abstract][Full Text] [Related]
12. Preoperative imatinib facilitates complete resection of locally advanced primary GIST by a less invasive procedure.
Yang W; Yu J; Gao Y; Shen Q; Zhang Q; Liu X; Zhao Z; Shi X; Zhu K; Ma Y
Med Oncol; 2014 Sep; 31(9):133. PubMed ID: 25056206
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Cao H; Zhang ZG
BMC Gastroenterol; 2014 Jun; 14():105. PubMed ID: 24906683
[TBL] [Abstract][Full Text] [Related]
14. Surgical management of gastrointestinal stromal tumours: a single centre experience during the past 17 years.
De Vogelaere K; Van De Winkel N; Aerts M; Haentjens P; Spitali C; Van Loo I; Delvaux G
Acta Chir Belg; 2014; 114(3):167-73. PubMed ID: 25102705
[TBL] [Abstract][Full Text] [Related]
15. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry.
Call J; Walentas CD; Eickhoff JC; Scherzer N
BMC Cancer; 2012 Mar; 12():90. PubMed ID: 22429770
[TBL] [Abstract][Full Text] [Related]
16. Current management of gastrointestinal stromal tumors--a comprehensive review.
Lai EC; Lau SH; Lau WY
Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
Gold JS; Gönen M; Gutiérrez A; Broto JM; García-del-Muro X; Smyrk TC; Maki RG; Singer S; Brennan MF; Antonescu CR; Donohue JH; DeMatteo RP
Lancet Oncol; 2009 Nov; 10(11):1045-52. PubMed ID: 19793678
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of adjuvant imatinib therapy in improving the prognosis of patients with colorectal gastrointestinal stromal tumours.
Li Y; Meng X
Ann R Coll Surg Engl; 2015 Apr; 97(3):215-20. PubMed ID: 26263807
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal stromal tumors: diagnosis and treatment.
Acín-Gándara D; Pereira-Pérez F; Castaño-Pascual A; Durán-Poveda M; Antequera-Pérez A; Miliani-Molina C
Cir Cir; 2012; 80(1):44-51. PubMed ID: 22472152
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
